CHTR vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 07, 2026

CHTR

53.0
AI Score
VS
CHTR Wins

MRNA

35.7
AI Score

Investment Advisor Scores

CHTR

53score
Recommendation
HOLD

MRNA

36score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CHTR MRNA Winner
Revenue 27.12B 534.00M CHTR
Net Income 2.46B -2.13B CHTR
Net Margin 9.1% -397.9% CHTR
Operating Income 6.27B -2.20B CHTR
ROE 14.5% -31.4% CHTR
ROA 1.6% -19.4% CHTR
Total Assets 155.62B 10.96B CHTR
Cash 509.00M 1.72B MRNA
Debt/Equity 5.54 0.09 MRNA
Current Ratio 0.36 2.29 MRNA
Free Cash Flow 2.50B -1.25B CHTR

Relative Price Performance (Last 90 Days)

CHTR 1M: -26.6% · 3M: -20.4% MRNA 1M: +40.0% · 3M: +156.6%

Current Technical Phase

CHTR

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.1%), weak momentum, RSI 27

RSI (14): 27.5 · Price: $106.96

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64

RSI (14): 63.6 · Price: $196.48

Fundamentals Snapshot

Metric CHTR MRNA
Market Cap — —
Forward P/E 2.5 -41.0
Trailing P/E 2.8 —
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin 0.6% -0.7%
Operating Margin 0.2% -5.6%
EPS 38.41 -7.36
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CHTR is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.